Skip to main content
Home Clinical Trials

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us

See what’s new.


Uplizna, an antibody therapy for immune diseases, is based on technology licensed from Duke University, developed by the late Dr. Thomas Tedder (Immunology, SOM) and colleagues.

Read More

FDA and EMA Accept Vorasidenib Regulatory Submissions for the Treatment of IDH-mutant diffuse glioma

This application of vorasidenib is based on licensed technology developed by Dr. Darell Bigner (Neurobiology, SOM) and colleagues.

Read More

CITI Program Begins Innovative Licensing Partnership with Duke University

Just ASK™ is copyrighted course material developed by Dr. Nadine Barrett (formerly Family Medicine and Community Health, SOM) on how to increase equity and diversity in clinical trials.

Read More

Duke is Inventive: A Century of Innovation at Duke University

A new Centennial physical and digital exhibit from OTC collects innovations, inventors, and companies spinning out of Duke University.

Read More

Humacyte Submits Biologics License Application (BLA) to U.S. FDA Seeking Approval of Human Acellular Vessel™ (HAV™) for the Treatment of Vascular Trauma

Humacyte is a Duke University start-up out of the lab of Dr. Laura Niklason (formerly Anesthesiology, SOM), co-founded with Drs. Juliana Blum and Shannon Dahl.

Read More

New Analyses from Pivotal Phase 3 INDIGO Study Reinforce Vorasidenib’s Potential to Change the Treatment Paradigm for IDH-Mutant Diffuse Glioma

This application of vorasidenib is based on licensed technology developed by Dr. Darell Bigner (Neurobiology, SOM) and colleagues.

Read More

Clinetic Announces Series A Funding Round Led by Sopris Capital

Clinetic is a medical records Duke start-up founded on technology developed by a team at the Duke Institute for Health Innovation

Read More

Newly Identified Lipid in Breast Milk Might Reduce Cerebral Palsy in Infants

Tellus Therapeutics, a neonatal white matter injury therapeutics start-up, was co-founded by Dr. Eric Brenner (Pediatrics, SOM)

Read More

Evecxia Therapeutics Reports Favorable Data From a Phase 1 Single Ascending Dose Safety/Tolerability/PK/PD Trial of EVX-301

Evecxia Therapeutics is a Duke University start-up, founded by inventors Drs. Jacob Jacobsen and Marc Caron (Cell Biology, SOM) around their serotonin synthesis amplification therapeutic technology for mental health applications.

Read More

1 2 3 5